noradrenaline sintetica 0,1 mg/ml infusionsvätska, lösning
sintetica gmbh - noradrenalintartrat (monohydrat) - infusionsvätska, lösning - 0,1 mg/ml - noradrenalintartrat (monohydrat) 0,2 mg aktiv substans
noradrenaline sintetica 0,2 mg/ml infusionsvätska, lösning
sintetica gmbh - noradrenalintartrat (monohydrat) - infusionsvätska, lösning - 0,2 mg/ml - noradrenalintartrat (monohydrat) 0,4 mg aktiv substans
noradrenaline sintetica 1 mg/ml koncentrat till infusionsvätska, lösning
sintetica gmbh - noradrenalintartrat (monohydrat) - koncentrat till infusionsvätska, lösning - 1 mg/ml - noradrenalintartrat (monohydrat) 2 mg aktiv substans
fenylefrin sintetica 8,2 mg/ml injektionsvätska, lösning
sintetica gmbh - fenylefrinhydroklorid - injektionsvätska, lösning - 8,2 mg/ml - fenylefrinhydroklorid 10 mg aktiv substans
fenylefrin sintetica 0,08 mg/ml injektions-/infusionsvätska, lösning
sintetica gmbh - fenylefrinhydroklorid - injektions-/infusionsvätska, lösning - 0,08 mg/ml - fenylefrinhydroklorid 0,1 mg aktiv substans
ephedrine sintetica 10 mg/ml injektionsvätska, lösning
sintetica gmbh - efedrinhydroklorid - injektionsvätska, lösning - 10 mg/ml - efedrinhydroklorid 10 mg aktiv substans
ephedrine sintetica 50 mg/ml injektionsvätska, lösning
sintetica gmbh - efedrinhydroklorid - injektionsvätska, lösning - 50 mg/ml - efedrinhydroklorid 50 mg aktiv substans
celdoxome pegylated liposomal
yes pharmaceutical development services gmbh - doxorubicinhydroklorid - breast neoplasms; ovarian neoplasms; multiple myeloma; sarcoma, kaposi - antineoplastiska medel - celdoxome pegylated liposomal is indicated in adults:as monotherapy for patients with metastatic breast cancer, where there is an increased cardiac risk. or treatment of advanced ovarian cancer in women who have failed a first-line platinum-based chemotherapy regimen. in combination with bortezomib for the treatment of progressive multiple myeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant. for treatment of aids-related kaposi’s sarcoma (ks) in patients with low cd4 counts (< 200 cd4 lymphocytes/mm3) and extensive mucocutaneous or visceral disease. celdoxome pegylated liposomal may be used as first-line systemic chemotherapy, or as second line chemotherapy in aids-ks patients with disease that has progressed with, or in patients intolerant to, prior combination systemic chemotherapy comprising at least two of the following agents: a vinca alkaloid, bleomycin and standard doxorubicin (or other anthracycline).
etoposid fresenius kabi 20 mg/ml koncentrat till infusionsvätska, lösning
fresenius kabi ab - etoposid - koncentrat till infusionsvätska, lösning - 20 mg/ml - bensylalkohol hjälpämne; etoposid 20 mg aktiv substans; etanol, vattenfri hjälpämne - etoposid
oxynorm 10 mg/ml injektionsvätska, lösning
mundipharma ab - oxikodonhydroklorid - injektionsvätska, lösning - 10 mg/ml - oxikodonhydroklorid 10 mg aktiv substans - oxikodon